Figure 12.The relationship of risk signature with chemotherapy response. Difference of IC50 value between high- and low-risk groups for common chemotherapeutics drugs including Bleomycin, Cisplatin, Docetaxel, Gefitinib, Gemcitabine, Paclitaxel, Vinblastine, and Vinorelbine.
